MONDAY, Dec. 16, 2024 (HealthDay News) — The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast cancer, a new study says. Women who took tamoxifen after undergoing a lumpectomy to remove ductal carcinoma in situ (DCIS)Continue Reading

FRIDAY, Dec. 13, 2024 (HealthDay News) — An experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast cancer, a new clinical trial shows. The drug, imlunestrant, improved progression-free survival in patients whose breast cancer was driven by the female hormone estrogen. TheContinue Reading

FRIDAY, Dec. 13, 2024 (HealthDay News) — A “watch-and-wait” strategy might be the best option for some women with early-stage, low-risk breast cancer. According to two new studies presented Thursday at the San Antonio Breast Cancer Symposium, active monitoring of ductal carcinoma in situ (DCIS) resulted in breast cancer recurrenceContinue Reading